▲ Peaking
Business
Boehringer returns to Sino Biopharma in $7.4B deal for preclinical TCEs, ADCs
Boehringer Ingelheim has entered a massive $7.4 billion oncology partnership with China's Sino Biopharma to develop preclinical cancer therapies.